Clinical trial · Interventional
Treatment of Multifocal Lung Adenocarcinoma
A Clinical Pathway for the Treatment of Multifocal Lung Adenocarcinoma Using Genome Sequencing
NCT01946100CI-TRIAL-00097636terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Funding ended prior to completion of enrollment.
Summary
Brief summary (as posted)
To gather preliminary safety and outcome data for the multimodality treatment of lung adenocarcinoma in the setting of multifocal BAC.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma | Adenocarcinoma | ONTOLOGY_EXACT | 0.90 |
| Carcinoma Non-small-cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Multifocal Lung Adenocarcinoma | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Multifocal Lung Adenocarcinoma
- interventionNames
- Genetic: Multifocal Lung Adenocarcinoma
Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- 2 years
- description
- Overall survival compared to survival for Stage IV NSCLC on NCCTG trials
Secondary outcomes (3)
- measure
- Progressive free survival
- timeFrame
- Every 3 months for 2 years
- description
- Progressive free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
* Patient must be \> 18 years of age * Two or more GGO's or solid lesions suspicious for multifocal disease. * Clinical diagnosis of N0 * No evidence of distant metastases * No prior intra-thoracic radiation therapy (NOTE: Previous radiotherapy as part of treatment for head and neck, breast, or other non-thoracic cancer is permitted.), previous chemotherapy, or surgical resection for non-small cell lung cancer (NSCLC). * No other cancer in the past 5 years except early stage prostate cancer, or basal cell of skin. * PFT's that show patient is capable of tolerating a lung resection. * Non-pregnant and non-lactating. Women of child-bearing potential must have a negative urine or serum pregnancy test to participate in the study. * Patient must be able to understand and willing to sign an IRB-approved informed consent document.
References
Publications (1)
- DERIVEDSaddoughi SA, Powell C, Stroh GR, Rajagopalan S, Bartholmai BJ, Boland JM, Aubry MC, Harmsen WS, Blackmon SH, Cassivi SD, Nichols FC, Reisenauer JS, Shen KR, Mansfield AS, Maldonado F, Peikert T, Wigle DA. Long-Term Survival and CANARY-Based Artificial Intelligence for Multifocal Lung Adenocarcinoma. Mayo Clin Proc Digit Health. 2024 Jan 11;2(1):44-52. doi: 10.1016/j.mcpdig.2023.10.006. eCollection 2024 Mar. PMID 40206677